Title:
DABIGATRAN CYCLIC ESTER DERIVATIVE, AND METHOD FOR PREPARATION AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2016/019844
Kind Code:
A1
Abstract:
The present invention relates to a dabigatran cyclic ester derivative, as represented by formula (I), and a stereoisomer or pharmaceutically acceptable salt thereof, as well as a use thereof in the preparation of a pharmaceutical used for prevention and treatment of a thromboembolic disorder; the structure is as represented by the formula (I), and the definitions of X1, X2, R1, and R2 are consistent with the description.
More Like This:
Inventors:
WEI YONGGANG (CN)
QIU GUANPENG (CN)
LEI BOLIN (CN)
QIU GUANPENG (CN)
LEI BOLIN (CN)
Application Number:
PCT/CN2015/086016
Publication Date:
February 11, 2016
Filing Date:
August 04, 2015
Export Citation:
Assignee:
SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D401/14; A61K31/4439; A61K31/497; A61P7/02; A61P9/00
Foreign References:
| CN102875533A | 2013-01-16 | |||
| CN103044404A | 2013-04-17 | |||
| CN102838588A | 2012-12-26 |
Other References:
YANG, XIAOZHI YANG ET AL.: "Design, Synthesis and Antithrombotic Evaluation of Novel Dabigatran Prodrugs Containing Methyl Ferulatea", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 7, 8 February 2013 (2013-02-08), pages 2091, XP028997370, ISSN: 0960-894X, DOI: doi:10.1016/j.bmcl.2013.01.126
Attorney, Agent or Firm:
BEIJING SANYOU INTELLECTUAL PROPERTY AGENCY LTD. (CN)
北京三友知识产权代理有限公司 (CN)
北京三友知识产权代理有限公司 (CN)
Download PDF:
Previous Patent: MULTI-ANTENNA IMPLEMENTATION METHOD, DEVICE AND SYSTEM
Next Patent: SODIUM SALT OF HCV NS3 PROTEASE INHIBITOR
Next Patent: SODIUM SALT OF HCV NS3 PROTEASE INHIBITOR